Grace Therapeutics Inc (GRCE)

$3.72 -0.03 (-0.93%)
Market Cap 56.17M
Revenue (ttm) 0.00
Net Income (ttm) -9.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 36,942
Avg Vol 88,158
Day's Range N/A - N/A
Shares Out 15.47M
Stochastic %K 61%
Beta 0.55
Analysts Strong Sell
Price Target $11.83

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgi...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 322 1602
Address:
103 Carnegie Center, Suite 300, Princeton, United States
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 2 at 6:57 PM
$GRCE
0 · Reply
Bellz22
Bellz22 Feb. 2 at 6:12 PM
$GRCE
0 · Reply
Bigmikewhph
Bigmikewhph Feb. 2 at 1:49 PM
$GRCE https://www.marketbeat.com/instant-alerts/grace-therapeutics-inc-nasdaqgrce-short-interest-up-346-in-january-2026-02-01/ Could anyone give me a logical reason why?
1 · Reply
Bellz22
Bellz22 Jan. 29 at 8:52 PM
$GRCE what’s everyone’s PT? I can’t wait till this explodes
3 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 27 at 2:03 PM
$GRCE LETS GO
0 · Reply
SuddenlyStocky
SuddenlyStocky Jan. 26 at 10:13 PM
$GRCE Not! Hold long if above MA20; target next resistance (e.g., prior highs). Stop below MA50 ($3.40). Low vol tempers aggression; scale in on volume spike.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 9:07 PM
$GRCE RSI: 61.36, MACD: 0.1071 Vol: 0.14, MA20: 3.63, MA50: 3.40 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 26 at 12:15 PM
$GRCE BUST THRU $4!!!!!! Come on
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 24 at 9:15 PM
$GRCE this one is going to blow
0 · Reply
FelixH86
FelixH86 Jan. 23 at 9:43 PM
$GRCE good week..
0 · Reply
Latest News on GRCE
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Nov 17, 2025, 8:00 AM EST - 2 months ago

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Nov 13, 2025, 8:00 AM EST - 2 months ago

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Nov 11, 2025, 8:30 AM EST - 3 months ago

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Oct 23, 2025, 8:00 AM EDT - 3 months ago

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Sep 22, 2025, 8:00 AM EDT - 4 months ago

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Sep 18, 2025, 8:30 AM EDT - 4 months ago

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 5 months ago

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 25, 2025, 8:00 AM EDT - 7 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 23, 2025, 8:00 AM EDT - 8 months ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Grace Therapeutics to Participate in the 2025 BIO International Conference

Jun 13, 2025, 8:00 AM EDT - 8 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Apr 9, 2025, 8:00 AM EDT - 10 months ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar 11, 2025, 7:00 AM EDT - 11 months ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 13, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Feb 10, 2025, 12:05 PM EST - 1 year ago

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:05 AM EST - 1 year ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Feb 10, 2025, 8:01 AM EST - 1 year ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Jan 7, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Acasti Pharma to Attend BIO International Convention 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

Acasti Pharma to Attend BIO International Convention 2024

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 12, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Feb 1, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Dec 13, 2023, 8:00 AM EST - 2 years ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 10, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 7, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jul 5, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 23, 2023, 7:00 AM EDT - 2 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Acasti Announces Appointment of New Scientific Advisory Board Members

Jun 22, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 17, 2023, 9:00 AM EDT - 2 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

May 8, 2023, 7:00 AM EDT - 2 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:01 AM EDT - 3 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Acasti Announces Appointment of Prashant Kohli as CEO

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Acasti Announces Appointment of Prashant Kohli as CEO

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 30, 2023, 8:30 AM EDT - 3 years ago

Acasti Pharma Inc. Announces the Resignation of a Director

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 13, 2023, 8:00 AM EDT - 3 years ago

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023, 9:00 AM EST - 3 years ago

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Acasti Pharma Recognizes Rare Disease Day

Feb 28, 2023, 1:00 PM EST - 3 years ago

Acasti Pharma Recognizes Rare Disease Day

CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 2 at 6:57 PM
$GRCE
0 · Reply
Bellz22
Bellz22 Feb. 2 at 6:12 PM
$GRCE
0 · Reply
Bigmikewhph
Bigmikewhph Feb. 2 at 1:49 PM
$GRCE https://www.marketbeat.com/instant-alerts/grace-therapeutics-inc-nasdaqgrce-short-interest-up-346-in-january-2026-02-01/ Could anyone give me a logical reason why?
1 · Reply
Bellz22
Bellz22 Jan. 29 at 8:52 PM
$GRCE what’s everyone’s PT? I can’t wait till this explodes
3 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 27 at 2:03 PM
$GRCE LETS GO
0 · Reply
SuddenlyStocky
SuddenlyStocky Jan. 26 at 10:13 PM
$GRCE Not! Hold long if above MA20; target next resistance (e.g., prior highs). Stop below MA50 ($3.40). Low vol tempers aggression; scale in on volume spike.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 9:07 PM
$GRCE RSI: 61.36, MACD: 0.1071 Vol: 0.14, MA20: 3.63, MA50: 3.40 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 26 at 12:15 PM
$GRCE BUST THRU $4!!!!!! Come on
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 24 at 9:15 PM
$GRCE this one is going to blow
0 · Reply
FelixH86
FelixH86 Jan. 23 at 9:43 PM
$GRCE good week..
0 · Reply
Mikshagav
Mikshagav Jan. 23 at 2:49 PM
$GRCE trust the process😙
0 · Reply
Pharma3000
Pharma3000 Jan. 23 at 2:29 PM
$GRCE Can you smell, its coming!
0 · Reply
Bellz22
Bellz22 Jan. 23 at 1:18 AM
$GRCE can’t wait till this takes off
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 22 at 4:44 PM
$GRCE up bigly today!
0 · Reply
shade00tree
shade00tree Jan. 22 at 4:29 PM
$GRCE yup
0 · Reply
shade00tree
shade00tree Jan. 22 at 4:25 PM
$GRCE
0 · Reply
FelixH86
FelixH86 Jan. 20 at 10:10 PM
$GRCE
0 · Reply
ViVega1
ViVega1 Jan. 20 at 9:22 PM
$GRCE What is wrong with this one? Honest question. Why it can't go up? ATM? We should be above 4 bucks imo. GL
1 · Reply
TimeForBio
TimeForBio Jan. 20 at 2:42 PM
$GRCE 📄 Jan 10, 2026 Filed an 8-K laying out what happens to management if the company gets acquired. Not saying a deal is coming... but this is classic M&A prep. You clean this up before talks, not after
0 · Reply
Mocki87
Mocki87 Jan. 15 at 7:14 PM
$OSTX and $GRCE strong buy "The Company is hopeful to gain regulatory approval for OST-HER2 in the UK in the second quarter of 2026, in the United States in the third quarter or 2026 and in Europe by the end of the fourth quarter of 2026."
0 · Reply
FelixH86
FelixH86 Jan. 14 at 7:43 PM
$GRCE
0 · Reply
shade00tree
shade00tree Jan. 14 at 6:26 AM
$GRCE I think you’re misinformed. Badly.
0 · Reply